Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Leukemia. 2024 Aug;38(8):1843-1847. doi: 10.1038/s41375-024-02282-y. Epub 2024 May 15.
No abstract available

Publication types

  • Letter

MeSH terms

  • Drug Repositioning* / methods
  • Drug Resistance, Neoplasm* / genetics
  • Fusion Proteins, bcr-abl* / antagonists & inhibitors
  • Fusion Proteins, bcr-abl* / genetics
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
  • Protein Kinase Inhibitors* / pharmacology
  • Protein Kinase Inhibitors* / therapeutic use

Substances

  • Protein Kinase Inhibitors
  • Fusion Proteins, bcr-abl
  • BCR-ABL1 fusion protein, human